AxoSim

AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim, BrainSim, and microBrainTM deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSims platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology. Is your organization interested in learning more about what we do? Please email us at info@axosim.com

Drug developent,preclinical testing,neurotoxicity,neuroefficacy,3d cell assays,neurodegenerative disease models,myelination models,nerve-on-a-chip,organ-on-a-chip,peripheral neuropathy,toxicology,neuroscience,and organoids

Axosim operates in the Biotechnology research industry.

Axosim's revenue is 11m - 100m

Axosim has 11 - 50 employees.